A Redox-active PARP Inhibitor for Lung Transplantation

用于肺移植的氧化还原活性 PARP 抑制剂

• 批准号: 8391286
• 负责人: ANDREW Lurie SALZMAN
• 金额: $ 39.07万
• 依托单位: RADIKAL THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-01 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8391286
• 关键词: 3-nitrotyrosine; Acute; Acute Lung Injury; Animal Model; Animals; Apoptosis; Area; Breathing; Bronchoalveolar Lavage; Catalysis; Cells; Cellularity; Chairperson; Chemistry; Chlorine; Clinical; Consumption; Cytoprotective Agent; DNA Repair Enzymes; Dose; Drug Delivery Systems; European; Excision; Exhibits; Experimental Models; F2-Isoprostanes; Flushing; Genes; Genetic; Histologic; Histology; Hydrogen Peroxide; IL6 gene; Immunohistochemistry; In Situ; Infarction; Inflammation; Inflammatory; Inhibitory Concentration 50; Injury; Intercellular adhesion molecule 1; Interleukin-1; Interleukin-6; Interruption; Ischemia; Isoprostanes; Left; Left lung; Legal patent; Life; Lipid Peroxidation; Lung; Lung Compliance; Lung Transplantation; MAPK14 gene; MAPK8 gene; Macrophage Inflammatory Protein-1; Measures; Mediating; Messenger RNA; Mitogen-Activated Protein Kinases; Modeling; Morbidity - disease rate; Multiple Organ Failure; Mus; Myocardial Ischemia; Necrosis; Neutrophil Infiltration; Nitrosation; North Carolina; Nuclear; Organ Transplantation; Orphan Drugs; Oxidation-Reduction; P-Selectin; Pathway interactions; Perfadex; Permeability; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacotherapy; Phosphorylation; Pneumonia; Poly Adenosine Diphosphate Ribose; Poly(ADP-ribose) Polymerases; Population; Prevention; Process; Property; Proteins; Pulmonary Edema; Pulmonary Vascular Resistance; Rattus; Relative (related person); Reperfusion Injury; Reperfusion Therapy; Residual state; Respiratory Failure; Resuscitation; Reverse Transcriptase Polymerase Chain Reaction; Risk; Rodent Model; Shock; Shunt Device; Single-Stranded DNA; Small Inducible Cytokine A3; Societies; Sprague-Dawley Rats; Stress; Structure of parenchyma of lung; Sulfhydryl Compounds; TNF gene; TNFRSF5 gene; Technology; Testing; Therapeutic; Thoracotomy; Time; Tissues; Translations; Universities; Vascular Permeabilities; Weight; Zymosan; catalase; catalyst; clinically relevant; commercialization; drug market; exhaust; experience; in vivo Model; indexing; inflammatory marker; inhibitor/antagonist; innovation; lung injury; lung ischemia; medical complication; mimetics; mortality; nitrosative stress; novel; novel therapeutics; oxidant stress; prevent; professor; prophylactic; protein B

DESCRIPTION (provided by applicant): Lung ischemia-reperfusion injury (IRI) is an acute lung injury that contributes to morbidity and mortality following lung transplantation (LTX). IRI i mediated in part by the synthesis of oxidative and nitrosative species that in turn induce DNA single strand breakage and triggering of the nuclear DNA repair enzyme, poly(ADP-ribose) polymerase-1 (PARP-1). Hyperactivation of PARP-1 results in the consumption of its substrate NAD, which in turn exhausts intracellular energetics, leading to ATP depletion and tissue necrosis. PARP-1 activation also induces a widespread expression of pro-inflammatory genes that contribute to vascular permeability, lung edema, neutrophil infiltration, pulmonary shunt, and respiratory failure. In models of IRI injury, genetic deletion or pharmacologic inhibition of PARP-1 potently reduces lung damage, but the extent of protection is subtotal. We propose a more thorough abrogation of IRI-induced tissue damage via the deployment of a bifunctional PARP-1 inhibitor, R-503, formed from the covalent linkage of 2 moieties, each with demonstrated tissue protection: 1) a PARP-1 inhibitor moiety, and 2) a thiol-rich dihydrolipoyl ("DHL") domain that acts as a broad-spectrum redox degradation catalyst. Aim #1: Establish the superiority of the bifunctional PARP-1 inhibitor, R-503, relative to its component domains, in a rat model of warm-ischemic lung IRI. Rat lungs are rendered ischemic in situ for 60 min and reperfused for 4 h. Prior to ischemia, rats are treated with IV R-503, DHL, the monofunctional PARP-1 inhibitor INO-1001, or a combination of DHL and INO-1001. Tissue damage is assessed by histology, levels of PMN infiltration, lipid peroxidation, NF-?B, protein nitrosation, PARP-1 activation, apoptosis, and oxygenation (PaO2). Inflammation is assessed by examining BAL markers of inflammation (protein, PMNs, TNF-¿, and MIP-1¿). Aim #2: Establish the efficacy of R-503 in a syngeneic rat model of orthotopic LTX. Using a translational model of LTX, donor rats are treated IV with R-503 or vehicle 10 min before lung removal. After flushing with cold Perfadex", spiked with R-503 (30 ¿M) or vehicle, donor lungs are stored cold for 12 h before left LTX. Right donor lungs are processed for immunohistochemical analysis of PARP-1 activation. Immediately following LTX with left donor lungs, recipients will receive R-503 or vehicle. The dose of R-503 will be guided by the optimal level elucidated in Aim #1. Recipient rats will be evaluated at 3 different reperfusion times (1, 3, 6 h) for wet/dry weight ratio, graft oxygenation, pulmonary vascular resistance, dynamic compliance, and lung F2¿-isoprostane, histology, and immunohistochemistry for 3-nitrotyrosine and poly(ADP-ribose). Specific analyses will be carried out at 3 time points: at 1 h post reperfusion for I?B¿, phosphorylation of MAP kinases, nuclear p50; at 3 h post reperfusion for RT-PCR to quantify lung mRNA concentrations of TNF-¿, MIP-1¿, and Bcl-2; and at 6 h post reperfusion for determination of BALF cellularity, protein concentration, TNF-¿, MIP-1¿, IL6, and IL1-¿. PUBLIC HEALTH RELEVANCE: Ischemia-reperfusion injury is a major medical complication following lung transplantation and contributes to the high mortality in this population. At present there are no approved prophylactic measures. We are developing a novel drug that targets the basic mechanisms of this condition and will test this agent in two clinically-relevant animal models.

描述（由适用提供）：肺部缺血再灌注损伤（IRI）是一种急性肺损伤，有助于肺移植后发病和死亡（LTX）。 IRI I部分是由氧化和亚硝化物质的合成，这些物种又诱导DNA单链断裂并触发核DNA修复酶，聚（ADP-核糖）聚合酶1（PARP-1）。 PARP-1的过度激活导致其底物NAD的消耗，进而耗尽细胞内能，从而导致ATP部署和组织坏死。 PARP-1激活还诱导了促炎基因的宽度表达，这些基因有助于血管通透性，肺水肿，中性粒细胞浸润，肺管分流和呼吸衰竭。在IRI损伤的模型中，PARP-1的遗传缺失或药物抑制可能会减少肺损伤，但保护程度是小计的。我们通过部署双功能PARP-1抑制剂R-503提出了更彻底的废除iri诱导的组织损伤，该抑制剂是由2个部分的共价连接形成的，每个抑制剂都具有组织保护：1）A PARP-1抑制剂部分和2个硫化二氢二氢二氢（Dihydrolipoyl）（dihydihydihydihydhydihydihlipoyl（dihydihydihydihylipoyl），催化剂。 AIM＃1：在温暖缺血性肺IRI的大鼠模型中，建立双功能PARP-1抑制剂R-503的超级性R-503。将大鼠肺在原位进行缺血，持续4小时。在缺血之前，用IV R-503，DHL，单功能PARP-1抑制剂INO-1001或DHL和INO-1001的组合对大鼠进行治疗。通过组织学，PMN浸润水平，脂质过氧化，NF-？B，蛋白硝化，PARP-1激活，凋亡和氧合（PAO2）评估组织损伤（PAO2）。通过检查感染的BAL标记（蛋白质，PMN，TNF- - 和MIP-1？）来评估炎症。 AIM＃2：在原位LTX的合成大鼠模型中建立R-503的效率。使用LTX的翻译模型，在去除肺前10分钟将供体大鼠用R-503或车辆处理。用R-503（30？m）或车辆加尖加的冷水液冲洗后，将供体肺部冷存储12小时，然后左LTX。处理PARP-1激活的右供体肺部以进行免疫组织化学分析。在LTX之后，LTX在LTX后立即受到左肺部的效果，将接收R-503或车辆的目标。 ＃1。 3-硝基酪氨酸和聚（ADP-核糖）的氧合，肺血管抗性，动态依从性和肺F2¿-异前烷，组织学和免疫组织化学。具体分析将在3个时间点进行：I？b¿的再灌注后1小时，磷酸化，磷酸化 MAP激酶，核P50； RT-PCR再灌注后3小时，以量化TNF- - ，MIP-1和Bcl-2的肺mRNA浓度；再灌注后6小时，用于测定BALF细胞，蛋白质浓度，TNF-€，MIP-1，IL6和IL1-®。 公共卫生相关性：缺血 - 重新灌注损伤是肺移植后的主要医学并发症，并导致该人群的高死亡率。目前尚无批准的预防措施。我们正在开发一种针对该疾病的基本机制的新型药物，并将在两个临床上相关的动物模型中测试该药物。